Verdiva Bio - About the company
Verdiva Bio is a series A company based in London (United Kingdom), founded in 2024 by Khurem Farooq. It operates as a Developer of oral and injectable peptide therapies for metabolic diseases. Verdiva Bio has raised $411M in funding from General Atlantic and Forbion. The company has 553 active competitors, including 165 funded and 150 that have exited. Its top competitors include companies like argenx, Rhythm Pharmaceuticals and MannKind Corp.
Company Details
Developer of oral and injectable peptide therapies for metabolic diseases. Research focuses on creating rationally engineered peptides to address obesity and related cardiometabolic conditions. The pipeline includes oral formulations of GLP-1 analogs and amylin-based candidates designed for once-weekly administration. These therapeutic programs utilize proprietary absorption enhancers to support delivery and manufacturing. The portfolio encompasses both monotherapies and combination treatments aimed at managing weight and metabolic health through various biological mechanisms.
- Website
- verdivabio.com
- Email ID
- *****@verdivabio.com
- Registered Address
- 25 AUSTEN ROAD, GUILDFORD, ENGLAND, GU1 3NP
Key Metrics
Founded Year
2024
Location
London, United Kingdom
Stage
Series A
Total Funding
$411M in 1 round
Latest Funding Round
Investors
Ranked
82nd among 553 active competitors
Annual Revenue
£0 - £1M as on Dec 31, 2025
Employee Count
78 as on Sep 30, 2026
Similar Companies
Legal entities associated with Verdiva Bio
Verdiva Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
VERDIVA BIO LIMITED CIN: 15863501 , United Kingdom, Active | Jul 29, 2024 | £0 - £1M (As on Dec 31, 2025) | - |
Sign up to download Verdiva Bio's company profile
Verdiva Bio's funding and investors
Verdiva Bio has raised a total funding of $411M over 1 round. Its latest funding round was a Series A round on Jan 09, 2025 for $*****. 7 investors participated in its latest round. Verdiva Bio has 7 institutional investors.
Here is the list of recent funding rounds of Verdiva Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 09, 2025 | 6753781 | Series A | 2401585 | 9010080 | 8568033 | 5094557 |
Access funding benchmarks and valuations. Sign up today!View details of Verdiva Bio's funding rounds and investors
Verdiva Bio's founders and board of directors
Founder? Claim ProfileThe founders of Verdiva Bio is Khurem Farooq. Khurem Farooq is the CEO of Verdiva Bio.
Here are the details of Verdiva Bio's key team members:
- Khurem Farooq: Co-Founder & CEO of Verdiva Bio. They are also an angel investor in 1 startup.Contact Info: 1 email address
View details of Verdiva Bio's Founder profiles and Board Members
Verdiva Bio's employee count trend
Verdiva Bio has 78 employees as of Sep 26. Here is Verdiva Bio's employee count trend over the years:
Uncover Verdiva Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Verdiva Bio's Competitors and alternates
Top competitors of Verdiva Bio include argenx, Rhythm Pharmaceuticals and MannKind Corp. Here is the list of Top 10 competitors of Verdiva Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 76/100 | ||
2nd | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 72/100 | |
3rd | MannKind Corp 1991, Los Angeles (United States), Public | Developer of small-molecule drugs | $50M | 71/100 | |
4th | Corcept 1998, Menlo Park (United States), Public | Developer of cortisol modulators for the treatment of various diseases | - | 69/100 | |
5th |  Vor Biopharma 2019, Cambridge (United States), Public | Developer of therapeutics to treat acute myeloid leukemia | $152M | 69/100 | |
6th |  Structure 2017, San Francisco (United States), Public | Developer of oral small molecule drugs for chronic diseases | $191M | 67/100 | |
7th | Tenaya Therapeutics 2016, San Francisco (United States), Public | Developer of regenerative and gene therapeutics for heart failure | $248M | 66/100 | |
8th | Kiniksa Pharmaceuticals 2015, Lexington (United States), Public | Developer of therapeutics for multiple diseases treatment | $320M | 65/100 | |
9th |  Rani Therapeutics 2012, San Jose (United States), Public | Developer of technology for the oral delivery of large drug molecules | $226M | 65/100 | |
10th | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 65/100 | ||
82nd | Verdiva Bio 2024, London (United Kingdom), Series A | Developer of oral and injectable peptide therapies for metabolic diseases | $411M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Verdiva Bio's competitors? Click here to see the top ones
Verdiva Bio's Investments and acquisitions
Verdiva Bio has made no investments or acquisitions yet.
Reports related to Verdiva Bio
Here is the latest report on Verdiva Bio's sector:
News related to Verdiva Bio
Filter this listMedia has covered Verdiva Bio for a total of 7 events in the last 1 year, 5 of them have been about company updates and 1 about partnerships.
•
Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing PotentialBusiness Wire•Jul 30, 2026•Verdiva Bio
•
Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical OfficerBusiness Wire•Jul 23, 2026•Verdiva Bio
•
Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug CandidatesBusiness Wire•Jun 05, 2026•Verdiva Bio
•
Verdiva Bio Completes Enrollment for VRB-101 Obesity Phase 2b StudyBusiness Wire•Feb 24, 2026•Verdiva Bio
•
•
Verdiva Bio and MitoRx Developing Next-Gen Obesity TherapiesBioSpace•Feb 19, 2026•Verdiva Bio, MitoRx Therapeutics
•
Kailera Therapeutics Secures $600M to Advance Obesity Drug Similar to ZepboundBioPharmaDive•Oct 14, 2025•Helicore Biopharma, Verdiva Bio, Kailera, Isomorphic Labs and 10 others
•
Eikon raises $351M in one of the year’s largest biotech venture roundsBioPharmaDive•Feb 26, 2025•Eikon, Merck, Seven and Eight Biopharmaceuticals, Verdiva Bio and 2 others
•
Two billion-plus deals among January’s largest announced transactionsInsider Media•Feb 03, 2025•Dowlais, Diversified Energy, GSK, Petershill Partners and 24 others
•
Verdiva Bio Raises Over $410M in Series A FinancingFinSMEs•Jan 13, 2025•Verdiva Bio, Orbimed, Logos, Lilly
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Verdiva Bio
Explore our recently published companies
- Alphaart.co.uk - United Kingdom based, Unfunded company
- Xa80b.org - Unfunded company
- Sports For Youth - United Kingdom based, Unfunded company
- Great Aspiration - Gold Coast based, 2022 founded, Unfunded company
- Zinance - San Francisco based, 2023 founded, Unfunded company
- Don Bosco Group of Institutions - Bengaluru based, 2015 founded, Unfunded company
